Author | J. Brantley Thrasher, MD


Are phase 3 HERO results a game-changer for urologists?

July 28, 2020

"This new therapy could change the landscape for the treatment of advanced prostate cancer," Thrasher writes.

Challenges remain for active surveillance in low-risk PCa

February 01, 2018

“Active surveillance continues to gain traction as a management strategy for low-risk prostate cancer in the United States. However, barriers still exist and challenges remain for both the treating urologist and the patient,” writes J. Brantley Thrasher, MD.

Renal biopsy may alter management in high-risk patients

January 01, 2016

In this interview, E. Jason Abel, MD, discusses biopsy’s role in small and large renal masses, associated risks, and when patients can be safely observed.

Immunotherapy will define new era of GU cancer care

December 31, 2014

In this interview, Arie Belldegrun, MD, discusses the benefits of cancer immunotherapy, the importance of a multidisciplinary treatment approach, and what the future holds for this treatment.